Guardian Bio
Biotech startup developing dendritic cell-based therapies to control immunity for cancer treatment.
About
Guardian Bio is developing a dendritic cell-based platform for cancer therapy, focused on controlling immunity using next-generation cell therapies. Co-founded in 2022 by Ananya Zutshi (BSE Duke, MS/MBA Harvard, Blavatnik Fellow) and Ricky Barrett, the YC-backed company is pioneering novel approaches to immuno-oncology. Guardian Bio has raised $500K from investors including Creative Destruction Lab, Brazen Capital, and Fundament. Teams look it up for AI, Biotech, Immuno-Oncology.
Frequently asked
What does Guardian Bio do?
Guardian Bio is an AI company. Teams look it up for Biotech, Immuno-Oncology, Cell Therapy. It is based in United States and was founded in 2022. Public records show about 5 people and $500K raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Guardian Bio raised?
Guardian Bio has raised a total of $500K in funding. The most recent round on record is Pre-Seed.
Where is Guardian Bio headquartered?
Guardian Bio is headquartered in United States.
When was Guardian Bio founded?
Guardian Bio was founded in 2022.
What industry does Guardian Bio operate in?
Guardian Bio operates in AI, Biotech, Immuno-Oncology, Cell Therapy.
How many employees does Guardian Bio have?
Guardian Bio has approximately 5 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.